Diasorin signed an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific, to place its Liaison NES rapid point-of-care qPCR system into U.S. hospital channels. The Liaison NES received FDA 510(k) clearance and a CLIA waiver in December for a respiratory assay that detects influenza A/B, SARS‑CoV‑2 and RSV in roughly 15 minutes with a three‑step workflow. Diasorin said the deal will accelerate its entry into more than 7,000 U.S. hospitals and complements an expanded Liaison NES salesforce. Carlo Rosa, Diasorin’s CEO, framed the agreement as critical to accessing integrated delivery networks and hospital procurement channels. The product targets the sub‑20‑minute, sample‑to‑answer molecular market already seeing competition from BioMérieux and startups such as Nuclein. For diagnostics firms, the Thermo Fisher channel offers scale and procurement reach that can materially change adoption curves for new POC platforms. Hospitals facing pressure to cut turnaround times for respiratory triage could accelerate capital and consumable purchases if the workflow and reimbursement align.